Cholestatic and Autoimmune Diseases SIG: Advancing AIH Understanding and Care
Recorded On: 11/09/2018
This program presents an update on the current state of knowledge about autoimmune hepatitis and identify the gaps in knowledge related to the immunologic, environmental, and genetic factors underlying AIH. The program will also review clinical management, identify unmet needs, and discuss barriers along the path toward development of new therapies for AIH.
Christopher L. Bowlus (Moderator)
Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.
Luca Fabris (Moderator)
With a Medical degree at Padua University, Italy (1987), Luca Fabris got his PhD at University of Milan, Italy (1997), after a research program developed at University of Birmingham, UK (1995-96). In 2005, he was nominated assistant Professor at the University of Padua, School of Medicine. Currently, as associate Professor in Gastroenterology, he leads a laboratory of experimental Hepatology in the Department of Molecular Medicine, in the same University.
Over the last 20 years, he has focused his scientific interests on topics related to pathophysiology of cholangiopathies, both of inflammatory and neoplastic origin, mainly with liver cell biology studies. From 2012, he has an appointment as adjunct Professor in the Yale University, CT, USA, where he is involved in the program of genetic biliary diseases and cancers.
On the clinical side, he has developed a longstanding experience, mostly devoted to the clinical management of rare liver diseases, in particular primary cholangiopathies. From 2012 to 2016, Dr Fabris was a steering committee member of the International Primary Sclerosing Cholangitis (PSC) Study Group, and from 2016, chair of the working group of ‘Malignancies in PSC’.
From 2016 to 2019, Dr Fabris is a steering committee member of the AASLD Special Interest Group on Cholestasis and Biliary Diseases.